Minerva Neurosciences to Present at JMP Securities Life Sciences Conference
Minerva Neurosciences, a clinical-stage biopharmaceutical firm, will present at the JMP Securities Life Sciences Conference on June 16, 2021, at 10:00 a.m. Eastern Time. The presentation will be accessible via a live and archived webcast on their investor relations website.
Minerva's key compounds include roluperidone for schizophrenia and MIN-301 for Parkinson’s disease. The company's common stock trades on NASDAQ under the symbol NERV.
- None.
- None.
WALTHAM, Mass., June 10, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will participate in the virtual JMP Securities Life Sciences Conference on June 16, 2021 at 10:00 a.m. Eastern Time.
The presentation will be webcast and accessible on a live and archived basis through the investor relations section of the Company’s web site, http://ir.minervaneurosciences.com.
About Minerva Neurosciences
Minerva’s portfolio of compounds includes: roluperidone (MIN-101), in clinical development for schizophrenia, and MIN-301, in pre-clinical development for Parkinson’s disease. Minerva’s common stock is listed on the NASDAQ Global Market under the symbol “NERV.” For more information, please visit www.minervaneurosciences.com.
William B. Boni
VP, Investor Relations/
Corp. Communications
Minerva Neurosciences, Inc.
(617) 600-7376
FAQ
When is Minerva Neurosciences participating in the JMP Securities Life Sciences Conference?
How can I access the webcast of Minerva Neurosciences' presentation?
What are the key products in Minerva Neurosciences' portfolio?
What is the stock symbol for Minerva Neurosciences?
